Byers Capital
VC Fund
Byers Capital is an investment firm.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Byers Capital invests in
Stages Byers Capital invests in
Countries Byers Capital invests in
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 7 (54%)
- Medical 4 (31%)
- Health Diagnostics 3 (23%)
- Software 2 (15%)
Stage
- Series A 6 (46%)
- Series B 2 (15%)
- Series C 2 (15%)
- Series D 1 (8%)
- Series E 1 (8%)
Country
- United States 12 (92%)
- Brazil 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oryon Cell Therapies
|
Oryon Cell treatments is a clinical-stage biotechnology business exploring autologous cell treatments for neurodegenerative illnesses, first focusing on Parkinson's disease. | $21M / Series A / Mar 23, 2026 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
ArsenalBio
|
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $325M / Series C / Sep 04, 2024 | |
PinkDx
|
PinkDx is a biotechnology company. | $40M / Series A / Apr 25, 2024 | |
Xaira Therapeutics
|
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area. | $1B / Series A / Apr 23, 2024 | |
Vial
|
Vial was founded to execute on a mission to reimagine clinical trials by delivering faster and more efficient trials for sponsors. Vial’s powerful technology platform delivers faster, more efficient trials that are up to 50% cheaper. | $67M / Series B / Nov 30, 2022 | |
Mombak
|
Mombak is a carbon removal company that focuses on the reforestation of the Amazon. The company's team combines experts in science, technology, forestry, and carbon markets | $18.9M / Venture - Series Unknown / Nov 03, 2022 | |
Waltz Health
|
Waltz will work with every partner in the pharmaceutical supply chain, including consumers, payers and pharmacies to create smarter, technology-enabled ways to price, distribute and prescribe medications. | $35M / Series A / Apr 26, 2022 | |
Ostro
|
Ostro is a health platform that personalized engagement solutions for life sciences. It creates informative connections between those who make medicines and those who take them. The platform helps millions of people live healthier lives by creating personalized healthcare journeys that boost engagement for consumers and HCPs and drive value forlife sciences brands. Ostro was founded in 2019 and is based in Miami, Florida. | $45M / Series B / Apr 15, 2022 | |
Getlabs
|
Getlabs is the leading platform for at-home diagnostics.Healthcare organizations use Getlabs to send mobile phlebotomists to patients’ homes and collect labs, vitals, and advanced diagnostics. By leveraging Getlabs, partners can improve patient adherence and close gaps in care with same-day, nationwide availability.Our team has raised $50M fromstrategic investors including the two largest diagnostic laboratories in the United States, Labcorp and Quest. Getlabs’ mission is to save lives by expanding access to diagnostics for everyone. | $20M / Series A / Feb 03, 2022 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Byers Capital invest in?
Byers Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Byers Capital last invest?
The most recent investment recorded for Byers Capital closed in Mar 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
